ArticlePloS one2011
Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- AI-Guided Chemotherapy Optimization in Lung Cancer Using Genomic and Survival Data.Journal of personalized medicine · 2025Article
- Regulator of G protein signaling 1 is a potential target in gastric cancer and impacts tumor-associated macrophages.Cancer science · 2024Article
- Blood regulator of G protein signalling 1 as a potential prognostic biomarker in surgical nonsmall cell lung cancer patients: Correlation with clinical features and survival.The clinical respiratory journal · 2024Article
- Thrombogenesis-associated genetic determinants as predictors of thromboembolism and prognosis in cervical cancer.Scientific reports · 2023Article
- A RGS7-CaMKII complex drives myocyte-intrinsic and myocyte-extrinsic mechanisms of chemotherapy-induced cardiotoxicity.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Tumor-intrinsicOncoimmunology · 2023Article
- Functional Assessment of Cancer-Linked Mutations in Sensitive Regions of Regulators of G Protein Signaling Predicted by Three-Dimensional Missense Tolerance Ratio Analysis.Molecular pharmacology · 2023Article
- RGS1 serves as an antitumor target to inhibit proliferation of NICN87-DR cells and tumor growth in the gastric cancer mouse model.Turkish journal of biology = Turk biyoloji dergisi · 2022Article
- Single-Cell Transcriptome Analysis Reveals RGS1 as a New Marker and Promoting Factor for T-Cell Exhaustion in Multiple Cancers.Frontiers in immunology · 2021Article
- Regulator of G protein signaling 10: Structure, expression and functions in cellular physiology and diseases.Cellular signalling · 2020Review
- Genetic Analysis of Rare Human Variants of Regulators of G Protein Signaling Proteins and Their Role in Human Physiology and Disease.Pharmacological reviews · 2018Review
- Non-small-cell lung cancer pathological subtype-related gene selection and bioinformatics analysis based on gene expression profiles.Molecular and clinical oncology · 2018Article
- NanoString-based breast cancer risk prediction for women with sclerosing adenosis.Breast cancer research and treatment · 2017Article
- RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression.Cancer research · 2017Article
- Article
- RGS6 as a Novel Therapeutic Target in CNS Diseases and Cancer.The AAPS journal · 2016Review
- Regulated genes in mesenchymal stem cells and gastric cancer.World journal of stem cells · 2015Article
- TINAGL1 and B3GALNT1 are potential therapy target genes to suppress metastasis in non-small cell lung cancer.BMC genomics · 2014Article
- S-score: a scoring system for the identification and prioritization of predicted cancer genes.PloS one · 2014Article
- Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma.Clinical epigenetics · 2013Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
The regulator of G-protein signaling (RGS) pathway plays an important role in signaling transduction, cellular activities, and carcinogenesis. We hypothesized that genetic variations in RGS gene family may be associated with the response of late-stage non-small cell lung cancer (NSCLC) patients to chemotherapy or chemoradiotherapy. We selected 95 tagging single nucleotide polymorphisms (SNPs) in 17 RGS genes and genotyped them in 598 late-stage NSCLC patients. Thirteen SNPs were significantly associated with overall survival. Among them, rs2749786 of RGS12 was most significant. Stratified analysis by chemotherapy or chemoradiation further identified SNPs that were associated with overall survival in subgroups. Rs2816312 of RGS1 and rs6689169 of RGS7 were most significant in chemotherapy group and chemoradiotherapy group, respectively. A significant cumulative effect was observed when these SNPs were combined. Survival tree analyses identified potential interactions between rs944343, rs2816312, and rs1122794 in affecting survival time in patients treated with chemotherapy, while the genotype of rs6429264 affected survival in chemoradiation-treated patients. To our knowledge, this is the first study to reveal the importance of RGS gene family in the survival of late-stage NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.